On August 19, Hims & Hers Health Inc. rose 5.26% in regular trading, trading at $29.04/share, with turnover of $104 million. The rally was driven by CEO Andrew Dudum's public rebuttal of FTC allegations during a CNBC interview.

Dudum addressed the FTC's claims that the company shared user health data with Meta and Snap, engaged in billing violations, and created subscription cancellation barriers. He characterized the allegations as stemming from misunderstandings of the company's business model, emphasizing that Hims & Hers is a \"positive disruptor\" focused on expanding healthcare accessibility. The FTC lawsuit, filed on July 30, had previously triggered a 12% single-day decline.

Management's assertive stance alleviated investor concerns surrounding the legal proceedings. The recovery was further supported by recent analyst upgrades, including Needham raising its target price to $42 and Morgan Stanley adjusting its target to $28 from $21. The company recently reported Q2 revenue of $753 million, up 38% year-over-year, and raised its full-year revenue guidance to $3.1-3.3 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)